HopeStage
Back to all studies
CompletedNCT04592809

Ketamine or midazolam for repeat suicidal behavior in adolescents

About this title

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

Read the official source — NCT04592809
Medication studyAges 13–18United StatesSuicide prevention
The study in practice

Understand this study

Who was this study for?

Listed age limits: 13 years to 18 years.

Listed locations
DallasSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 3, 2022
Recruitment status
Completed
Enrollment listed in the registry
50
Sponsor
University of Texas Southwestern Medical Center
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 13 Years to 18 Years
Official registry ID
NCT04592809
Official title
Show the full official title

Double-Blind Randomized Controlled Trial of Acute-Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Dallas

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Texas Southwestern Medical Center, a university.

Did this study involve medication?

Yes. The study involved medication, including Ketamine Hydrochloride and Midazolam Hydrochloride.

Who was this study for?

Listed age limits: 13 years to 18 years.

Want to explore more studies?

Explore studies